arrow
G

Gintsburg, Alexander L.

ministry of health of the russian federation
H指数:0
被引数:35

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Immunogenicity and Efficacy of Combined mRNA Vaccine Against Influenza and SARS-CoV-2 in Mice Animal Models

流感和SARS-CoV-2 mRNA联合疫苗在小鼠动物模型中的免疫原性和有效性

2024-10-241
OAAI
Immunogenicity and Protectivity of Sputnik V Vaccine in hACE2-Transgenic Mice against Homologous and Heterologous SARS-CoV-2 Lineages Including Far-Distanced Omicron BA.5

Sputnik V疫苗在hACE2-Transgenic小鼠中针对同源和异源SARS-CoV-2谱系 (包括远距离Omicron BA.5) 的免疫原性和保护性

2024-10-080
OAAI
Development of novel antimicrobials with engineered endolysin LysECD7-SMAP to combat Gram-negative bacterial infections
2024-07-241
OAAI
Trivalent mRNA vaccine-candidate against seasonal flu with cross-specific humoral immune response
2024-04-163
OAAI
Major Role of S-Glycoprotein in Providing Immunogenicity and Protective Immunity in mRNA Lipid Nanoparticle Vaccines Based on SARS-CoV-2 Structural Proteins

基于SARS-CoV-2结构蛋白的mRNA脂质纳米粒疫苗中S-糖蛋白在提供免疫原性和保护性免疫中的主要作用

2024-04-022
OAAI
Synthesis and Antiviral Activity of Novel β-D-N4-Hydroxycytidine Ester Prodrugs as Potential Compounds for the Treatment of SARS-CoV-2 and Other Human Coronaviruses

新型 β-d-n4-羟基胞苷酯前药的合成和抗病毒活性,作为治疗SARS-CoV-2和其他人类冠状病毒的潜在化合物

2023-12-262
OAAI
Real-world clinical effectiveness of Tixagevimab/Cilgavimab and Regdanvimab monoclonal antibodies for COVID-19 treatment in Omicron variant-dominant period
2023-10-201
OAAI
In Vitro Efficacy of Antivirals and Monoclonal Antibodies against SARS-CoV-2 Omicron Lineages XBB.1.9.1, XBB.1.9.3, XBB.1.5, XBB.1.16, XBB.2.4, BQ.1.1.45, CH.1.1, and CL.1
2023-09-2816
OAAI
Safety and immunogenicity of rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine against SARS-CoV-2 in healthy adolescents: an open-label, non-randomized, multicenter, phase 1/2, dose-escalation study

基于rAd26和rAd5载体的异源初免-加强新型冠状病毒肺炎疫苗对健康青少年SARS-CoV-2的安全性和免疫原性: 一项开放标签、非随机、多中心、1/2期、剂量递增研究

2023-08-014
OAAI
rAAV expressing recombinant antibody for emergency prevention and long-term prophylaxis of COVID-19
2023-03-306
OAAI
Single-domain antibody delivery using an mRNA platform protects against lethal doses of botulinum neurotoxin A
2023-02-1415
OAAI
Revaccination in Age-Risk Groups with Sputnik V Is Immunologically Effective and Depends on the Initial Neutralizing SARS-CoV-2 IgG Antibodies Level

在年龄风险人群中使用Sputnik V进行再接种具有免疫学效果,并且取决于初始中和SARS-CoV-2 IgG抗体水平

2022-12-303
OAAI
Sputnik Light and Sputnik V Vaccination Is Effective at Protecting Medical Personnel from COVID-19 during the Period of Delta Variant Dominance

Sputnik Light和Sputnik V疫苗接种可有效保护医务人员在三角洲变体占主导地位期间免受新型冠状病毒肺炎

2022-10-268
OAAI
Immunogenicity and protectivity of intranasally delivered vector-based heterologous prime-boost COVID-19 vaccine Sputnik V in mice and non-human primates

鼻内递送的基于载体的异源启动-加强新型冠状病毒肺炎疫苗Sputnik V在小鼠和非人灵长类动物中的免疫原性和保护性

2022-09-2610
OAAI
An open, non-randomised, phase 1/2 trial on the safety, tolerability, and immunogenicity of single-dose vaccine Sputnik Light for prevention of coronavirus infection in healthy adults
2021-12-0142
OAAI
A Deep Look Into COVID-19 Severity Through Dynamic Changes in Blood Cytokine Levels
2021-11-0924
OAAI
Neutralizing Activity of Sera from Sputnik V-Vaccinated People against Variants of Concern (VOC: B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.617.3) and Moscow Endemic SARS-CoV-2 Variants

Sputnik V疫苗接种人群的血清对关注变体 (VOC: B.1.1.7,B.1.351,P.1,B.1.617.2,B.1.617.3) 和莫斯科地方性SARS-CoV-2变体的中和活性

2021-07-1288
OAAI